The inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium will take place February 17-18, 2026, in Palm Desert, California and online. This new meeting brings together experts from radiation oncology, nuclear medicine, medical physics, pharmacy and health systems operations to share advances in the rapidly expanding field of radiopharmaceutical therapy (RPT) in cancer care. Media information is available at astro.org/RPTpress, and general registration is available on the meeting website.

Radiopharmaceuticals are a type of specialized, systemic medicine where doctors inject targeted radiation to destroy tumor cells while limiting exposure to surrounding tissues. As the number of approved agents and the demand for these treatments grow, clinical teams and health systems are increasingly seeking guidance on building and sustaining RPT services for their communities. This new symposium will offer practical strategies and multidisciplinary perspectives to support both early adopters and teams scaling their programs.

Program highlights include:

• Keynote remarks from Stephen M. Hahn, MD, FASTRO, Chief Executive Officer and Board Chair of Nucleus RadioPharma and former Commissioner of the U.S. Food and Drug Administration, and Johannes Czernin, MD, Chief of the Ahmanson Translational Imaging Division at UCLA Health.

• Multidisciplinary sessions on radiation safety, regulatory considerations, staffing and workflow design and clinical integration across oncology and nuclear medicine.

• Case-based discussions exploring patient pathways, operational readiness and lessons learned from programs at various stages of implementation.

• Panels on the expanding pipeline of next-generation RPT agents, manufacturing, supply chain concerns and opportunities to expand access to RPT nationwide including workforce development issues.

• Networking and collaboration opportunities for clinicians, physicists, researchers, administrators and industry partners.

For more information, visit our press kit.

ABOUT ASTRO
The American Society for Radiation Oncology (ASTRO) is the world’s largest professional society dedicated to advancing radiation oncology, with 10,000 members including physicians, nurses, physicists, radiation therapists, dosimetrists and other professionals who work to improve patient outcomes through clinical care, research, education and policy advocacy. Radiation therapy is integral to 40% of cancer cures worldwide, and more than one million Americans receive radiation treatments for their cancer each year. For information on radiation therapy, visit RTAnswers.org. To learn more about ASTRO, visit our website and media center and connect with us on social media.